Ensayo BD ONCLARITY para determinar la prevalencia de genotipos de HPV en centros hospitalarios de Quito

Abstract

Being the Human Papillomavirus (HPV) the main cause of cervical cancer (CaCu) and one of the sexually transmitted diseases that has occurred in recent years, it is necessary to develop molecular tests to detect the human papillomavirus (HPV) and since conventional cytology has a low sensitivity according to randomized controlled trials, there is an urgent need to reduce the incidence and mortality of cervical cancer. Gradually, primary detection of the virus has been accepted as part of health policies in certain countries, with which it has been sought to have greater sensitivity to detect preneoplastic lesions, greater safety of negative tests, and longer detection intervals. It is still frequent and necessary to have assays for the detection of HPV that are validated and approved for its use, as well as guidelines for the management of positive cases, especially in developing countries where the incidence of cervical cancer is high. The study proposes the use of an FDA-approved molecular and liquid cytology assay in the female population of Quito-Ecuador, to establish the prevalence of the Human Papilloma Virus.